Van Lanschot Kempen Investment Management N.V. Has $338,000 Position in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Van Lanschot Kempen Investment Management N.V. reduced its stake in Vertex Pharmaceuticals by 79.3% in the first quarter, holding 698 shares worth $338,000 as of its latest SEC filing.
• Vertex Pharmaceuticals reported $4.52 earnings per share in its quarterly results, surpassing analysts' expectations of $4.24 and marking an 11.3% revenue increase year-over-year.
• Institutional investors and hedge funds now own 90.96% of Vertex Pharmaceuticals' stock, reflecting significant interest in the company's performance and growth potential.

Van Lanschot Kempen Investment Management N.V. lowered its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 79.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 698 shares of the pharmaceutical company's stock after selling 2,682 shares during the quarter. Van Lanschot Kempen Investment Management N.V.'s holdings in Vertex Pharmaceuticals were worth $338,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Brighton Jones LLC raised its stake in shares of Vertex Pharmaceuticals by 15.0% in the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock valued at $1,783,000 after acquiring an additional 579 shares during the last quarter. Transce3nd LLC bought a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $50,000. TD Waterhouse Canada Inc. raised its stake in shares of Vertex Pharmaceuticals by 260.2% in the fourth quarter. TD Waterhouse Canada Inc. now owns 8,840 shares of the pharmaceutical company's stock valued at $3,560,000 after acquiring an additional 6,386 shares during the last quarter. Stifel Financial Corp raised its stake in shares of Vertex Pharmaceuticals by 32.3% in the fourth quarter. Stifel Financial Corp now owns 124,844 shares of the pharmaceutical company's stock valued at $50,275,000 after acquiring an additional 30,512 shares during the last quarter. Finally, Dark Forest Capital Management LP raised its stake in shares of Vertex Pharmaceuticals by 54.6% in the fourth quarter. Dark Forest Capital Management LP now owns 1,657 shares of the pharmaceutical company's stock valued at $667,000 after acquiring an additional 585 shares during the last quarter. Institutional investors own 90.96% of the company's stock.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the acquisition, the director directly owned 45,000 shares of the company's stock, valued at approximately $17,535,600. This represents a 12.50% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on VRTX. Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. The Goldman Sachs Group reiterated a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Scotiabank reduced their target price on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a "sector perform" rating on the stock in a research report on Tuesday, August 5th. Cantor Fitzgerald reduced their target price on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 5th. Finally, Wall Street Zen lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and thirteen have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $497.10.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock traded down $2.34 during trading hours on Friday, reaching $395.12. 1,403,298 shares of the company were exchanged, compared to its average volume of 2,534,666. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The stock's fifty day moving average is $438.99 and its two-hundred day moving average is $461.34. The company has a market cap of $101.30 billion, a price-to-earnings ratio of 28.24 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same period in the prior year, the business posted ($12.83) earnings per share. Vertex Pharmaceuticals's revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.